CLOSED
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, tech. Track INDEGENE LIMITED's live NSE:INDGN share price ₹544.60 (+5.83%), market cap ₹₹131B, P/E 32.8. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for INDGN — real-time NSE India stock intelligence.
Open
₹523.45
High
₹554.85
Low
₹512.30
Prev. Close
₹514.60
52W High
₹596.80
52W Low
₹414.00
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, tech
Key Takeaway
INDEGENE LIMITED is rated buy with a P/E of 32.8x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is INDEGENE LIMITED fairly valued right now?
Because a P/E of 32.8x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting INDEGENE LIMITED
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
1,063 Cr
Revenue
116 Cr
Net Profit
0%
ROE
0%
ROCE
16.59
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 2,306 | 2,590 | 2,839 | 3,510 | 3,769 |
| Net Profit | 266 | 337 | 407 | 401 | 415 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | 16.59 | 16.59 |
| Debt/Equity | — | — | — | 5.0 | 5.0 |